Adamis Pharmaceuticals Corporation (ADMP) has committed to fund a research grant to the Leiden University Medical Center (LUMC) Anesthesia and Pain Research Unit. The funding will support the work of Albert Dahan, MD, PhD, an expert on opioid-induced respiratory depression. The collaboration aims to assess the efficacy of 5mg intramuscular ZIMHI versus 4mg of intranasal naloxone, which is comparable to NARCAN®. The CEO of Adamis believes that if ZIMHI demonstrates superiority in reversing fentanyl-induced respiratory depression, national health organizations will update their emergency protocols to include the use of ZIMHI.